Logo image of ASND

ASCENDIS PHARMA A/S - ADR (ASND) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ASND - US04351P1012 - ADR

205.89 USD
-9.15 (-4.26%)
Last: 1/16/2026, 4:00:58 PM
205.83 USD
-0.06 (-0.03%)
After Hours: 1/16/2026, 4:00:58 PM

ASND Key Statistics, Chart & Performance

Key Statistics
Market Cap12.46B
Revenue(TTM)646.55M
Net Income(TTM)-232.94M
Shares60.49M
Float58.64M
52 Week High229.94
52 Week Low118.03
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-4.49
PEN/A
Fwd PE54.47
Earnings (Next)02-10
IPO2015-01-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ASND short term performance overview.The bars show the price performance of ASND in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

ASND long term performance overview.The bars show the price performance of ASND in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of ASND is 205.89 USD. In the past month the price increased by 1.38%. In the past year, price increased by 67.83%.

ASCENDIS PHARMA A/S - ADR / ASND Daily stock chart

ASND Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 88.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ASND Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ASND. ASND has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ASND Financial Highlights

Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 48.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.17%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%41.86%
Sales Q2Q%269.4%
EPS 1Y (TTM)48.33%
Revenue 1Y (TTM)97.46%

ASND Forecast & Estimates

23 analysts have analysed ASND and the average price target is 271.25 USD. This implies a price increase of 31.75% is expected in the next year compared to the current price of 205.89.

For the next year, analysts expect an EPS growth of 50.58% and a revenue growth 127.84% for ASND


Analysts
Analysts88.7
Price Target271.25 (31.75%)
EPS Next Y50.58%
Revenue Next Year127.84%

ASND Ownership

Ownership
Inst Owners103.76%
Ins Owners0.76%
Short Float %5.78%
Short Ratio5.48

ASND Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.68 378.84B
AMGN AMGEN INC 15.11 177.91B
GILD GILEAD SCIENCES INC 15.25 155.00B
VRTX VERTEX PHARMACEUTICALS INC 25.42 111.97B
REGN REGENERON PHARMACEUTICALS 16.28 77.01B
ALNY ALNYLAM PHARMACEUTICALS INC 703.55 47.40B
INSM INSMED INC N/A 34.44B
NTRA NATERA INC N/A 31.89B
BIIB BIOGEN INC 9.82 24.11B
RVMD REVOLUTION MEDICINES INC N/A 23.26B
INCY INCYTE CORP 16.54 20.84B
UTHR UNITED THERAPEUTICS CORP 17.62 20.02B

Related stock screener links

About ASND

Company Profile

ASND logo image Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Company Info

ASCENDIS PHARMA A/S - ADR

Tuborg Boulevard 12

Hellerup 2900 DK

CEO: Jan Moller Mikkelsen

Employees: 1017

ASND Company Website

ASND Investor Relations

Phone: 4570222244

ASCENDIS PHARMA A/S - ADR / ASND FAQ

Can you describe the business of ASCENDIS PHARMA A/S - ADR?

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).


What is the current price of ASND stock?

The current stock price of ASND is 205.89 USD. The price decreased by -4.26% in the last trading session.


Does ASND stock pay dividends?

ASND does not pay a dividend.


What is the ChartMill technical and fundamental rating of ASND stock?

ASND has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the analyst forecast for ASND stock?

23 analysts have analysed ASND and the average price target is 271.25 USD. This implies a price increase of 31.75% is expected in the next year compared to the current price of 205.89.


Can you provide the number of employees for ASCENDIS PHARMA A/S - ADR?

ASCENDIS PHARMA A/S - ADR (ASND) currently has 1017 employees.


What is the outstanding short interest for ASCENDIS PHARMA A/S - ADR?

The outstanding short interest for ASCENDIS PHARMA A/S - ADR (ASND) is 5.78% of its float.